EMMPRIN is a transmembrane glycoprotein expressed at high levels by tumor cells. It has been identified as a tumor-derived factor that can stimulate matrix metalloproteinase expression in fibroblasts and hence facilitate tumor invasion and metastasis. Recent studies have shown that full-length EMMPRIN is released by tumor cells, but the mechanism of release remains unclear. Here, we show that EMMPRIN is released from the surface of NCI-H460 cells via microvesicle shedding. However, these vesicles are unstable and rapidly break down to release bioactive EMMPRIN. Although microvesicle shedding has been considered a constitutive process in tumor cells, our data show that it can be amplified upon cell exposure to PMA, elucidating at least one signalling cascade responsible for EMMPRIN release. This pathway is dependent on protein kinase C, calcium mobilization and mitogen-activated protein kinase kinase (MEK 1/2). Thus, the results outline a novel form of tumor-stromal interaction in which extracellular matrix degradation by fibroblasts is controlled through the microvesicular release of EMMPRIN from tumor cells.
Introduction
Epithelial-stromal interactions are necessary for tumor growth, but the molecular basis for such interactions is poorly understood (Basbaum and Werb, 1996; Liotta and Kohn, 2001) . One candidate to mediate such interactions is extracellular matrix metalloproteinase inducer (EMMPRIN, also known as basigin and CD147). This membrane-associated glycoprotein was initially discovered as a component of tumor-conditioned medium that was able to stimulate the production of matrix metalloproteinases (MMPs) in fibroblasts (Biswas et al., 1995) . Subsequent studies, using either purified native or recombinant EMMPRIN, have confirmed this (Guo et al., 1997; Lim et al., 1998; Li et al., 2001; Taylor et al., 2002) . Consistent with these in vitro studies, the degree of MMP expression by stromal fibroblasts has been shown to be correlated with EMMPRIN expression levels in a wide range of tumors (Caudroy et al., 1999; Dalberg et al., 2000; Thorns et al., 2002) . One outcome of MMP induction by tumorassociated EMMPRIN would likely be the local degradation of extracellular matrix (ECM); this, in turn, would facilitate tumor growth and metastasis.
Although it is clear that tumor-released EMMPRIN can influence MMP production in surrounding fibroblasts, many aspects of the phenomenon remain unclear. Chief among these are (i) the identity of the EMMPRIN receptor on fibroblasts, (ii) the cytoplasmic signalling events following EMMPRIN-receptor binding, although these have begun to be addressed (Lim et al., 1998; Taylor et al., 2002) , and (iii) the means by which EMMPRIN is released from epithelial cells. This report focuses on the last of these issues.
EMMPRIN is a cell surface type I transmembrane glycoprotein and is a member of a well-characterized immunoglobulin (Ig) superfamily whose members play important roles in cell surface recognition (e.g. NCAM, MHCII and CD8; Williams and Barclay, 1988; Miyauchi et al., 1990 Miyauchi et al., , 1995 Kanekura et al., 1991) . Such proteins are oriented with their N-termini outside and their C-termini inside the cell. One possible release mechanism for such proteins is proteolytic cleavage of the N-terminal ectodomain (e.g. HB-EGF and L1 adhesion molecule; Beer et al., 1999; Prenzel et al., 1999; Lemjabbar and Basbaum, 2002) . Alternatively, transmembrane proteins can be released in toto via mechanisms involving vesicle shedding (Satta et al., 1994; Heijnen et al., 1999; MacKenzie et al., 2001; Gutwein et al., 2003) . These possibilities can generally be distinguished by examination of the released protein: exclusive presence of the N-terminal domain would suggest proteolysis, whereas the presence of both N-and C-terminal domains would suggest vesicle release. A recent report by Taylor et al. (2002) presents a paradox in showing that although both the N-and C-terminal domains of EMMPRIN were released into tumorconditioned medium, there was no apparent association with vesicles. These findings led the authors to speculate that EMMPRIN was not a transmembrane glycoprotein (Taylor et al., 2002) .
The results described below clarify this issue by showing that extracellular EMMPRIN is indeed asso-ciated with vesicles shortly after release from the cell, but that these vesicles are degraded over time, giving rise to increasing levels of EMMPRIN in nonvesicle (i.e. supernatant) fractions of cell-conditioned medium.
Vesicle shedding has been observed in normal cells under certain physiological conditions (Dainiak, 1991; Heijnen et al., 1999; MacKenzie et al., 2001) , but is present at much higher rates in tumor cells (Black 1980; Taylor and Black, 1986) . The shedding of tumor surface antigens in membrane vesicles has been implicated as an important feature of malignant transformation. Although vesicle shedding has been linked to the protection of tumors against immune surveillance (Taylor and Black, 1986; Dolo et al., 1995; Albanese et al., 1998; Wolfers et al., 2001) , and to angiogenesis (Kim et al., 2002) , the present data are the first to demonstrate an additional role for vesicles, that is as vehicles for EMMPRIN in tumor-stromal interactions.
Results

EMMPRIN, an integral membrane protein, is released from tumor cells and stimulates MMP-1 transcription in fibroblasts
To examine the mechanism by which EMMPRIN is released from tumor cells, we studied the lung carcinoma lines NCI-H460 and NCI-H292. Immunocytochemical staining confirmed that both cell types expressed EMMPRIN on the cell surface ( Figure 1a , NCI-H292 cells not shown). In agreement with this, Western blots of cell lysates probed with an anti-EMMPRIN antibody were strongly immunoreactive ( Figure 1b) . We also detected EMMPRIN in tumor-cell-conditioned medium (Figure 1b ). That this EMMPRIN was not only active, but was also the principal MMP1-stimulating factor in conditioned medium was shown using assays in which a luciferase reporter was placed under the control of the MMP-1 promoter (Figure 1c) . The results showed that conditioned medium stimulated 16LU fibroblasts to increase MMP1 promoter-driven luciferase expression B2.7-fold, but that immunodepletion of EMMPRIN from the medium abolished this effect (Figure 1c) .
The EMMPRIN C-terminus is released into tumor-conditioned medium As mentioned above, transmembrane proteins such as EMMPRIN may be released from cells either by proteolytic cleavage of the N-terminal ectodomain, or by the outward budding of vesicles containing both Nand C-termini. To distinguish between these possibilities, we harvested cell lysate and conditioned medium from NCI-H460 cells and processed them for Western blots using N-and C-terminus-directed antibodies. The results in Figure 2a show that bands of the same size (49 kDa) were recognized by both antibodies in lysates and conditioned medium of tumor cells. Furthermore, the results of experiments in which a C-terminal FLAGtagged recombinant EMMPRIN expression vector was transfected into NCI-H460 cells confirmed the presence of the EMMPRIN C-terminus in the conditioned 
Full-length EMMPRIN is released via the shedding of microvesicles
The presence of full-length EMMPRIN in tumorconditioned medium suggested that EMMPRIN was released via vesicles. To test this, we precleared large debris from conditioned medium and then ultracentrifuged the supernatant to bring down vesicles. Electron microscopy of the ultracentrifuged pellet revealed that NCI-H460 cells shed two distinct populations of extracellular vesicles: small, spherical shaped vesicles (B100 nm or less), which fit the description of exosomes (Figure 3a , arrowheads) and larger vesicles (B300-400 nm), which fit the description of plasma membranederived microvesicles ( Figure 3a ; Pan et al., 1985; Heijnen et al., 1999; Mack et al., 2000; MacKenzie et al., 2001; Taraboletti et al., 2002; Thery et al., 2002) . The microvesicles, but not the exosomes, were clearly associated with immunoreactive EMMPRIN. Western blots of vesicle fractions also contained an EMMPRINpositive band at B49 kDa ( Figure 3b We were initially surprised that not only the vesicle fraction, but also the overlying supernatant contained EMMPRIN. We reasoned that this could arise either by ectodomain cleavage (see above) or alternatively by vesicle lysis. That supernatant EMMPRIN was unlikely to have been derived via proteolytic cleavage of the N-terminal ectodomain was apparent from both the presence of C-terminal immunoreactivity ( Figure 3b ) and the absence of small cleavage products. In contrast, results showing a time-dependent loss of vesicle protein ( Figure 3c ) and an inverse relationship between the amounts of EMMPRIN in vesicles versus supernatant over time (Figure 3d ) suggested that once released from the cell, microvesicles underwent degradation, releasing EMMPRIN into the supernatant. Our EM analysis of vesicle preparations after prolonged storage at either 4 or 371C showed a progressive disruption of vesicle structure, although EMMPRIN staining was still present on membrane fragments (data not shown). Unfortunately, the mechanism of vesicle degradation remains unclear at this time. The supernatant contained the principal stimulus for MMP-1 promoter activity. Combining vesicles and supernatant reconstituted the activity of the unfractionated conditioned medium (Figure 3e ).
Control of EMMPRIN release by PMA
Having shown that EMMPRIN was released through the shedding of microvesicles, we next asked whether this process could be controlled physiologically. We exposed NCI-H460 and NCI-H292 cells to a variety of stimuli including the tumor promoter PMA. The results in Figure 4a and b show that PMA stimulated EMMPRIN release in a time-and dose-dependent manner. The appearance of EMMPRIN in the medium was accompanied by a slight loss from cell lysates ( Figure 4c ). As expected, the amount of EMMPRIN in vesicle fractions increased in response to PMA (Figure 4d ).
Signalling pathway mediating EMMPRIN release
As an analogue of diacylglycerol (DAG), PMA binds to and stimulates protein kinase C (PKC), thereby also stimulating Ca 2 þ mobilization and various downstream The supernatant is the principal source of bioactive EMMPRIN in NCI-H460 8-h conditioned medium. Ultracentrifugation fractions (vesicles, VES and supernatant, SUP) or whole conditioned medium (CM) were applied to 16LU fibroblasts transfected with MMP-1 promoter-driven luciferase reporter constructs for 12 h. MMP-1 promoter response to conditioned medium or medium fractions is plotted as fold increase over activity in cells exposed to SFM alone. All assays were carried out in triplicate. showing that thapsigargin, which evokes the release of Ca 2 þ from endoplasmic reticulum, also stimulated the response (Figure 5b ). That this was diminished by exposure of cells to the MEK1/2 inhibitor PD90859 suggested that Ca 2 þ acts upstream of Erk 1/2 in the PMA-triggered pathway controlling EMMPRIN release.
Discussion
EMMPRIN has been recognized as a tumor cell mediator with effects on fibroblast protease production for over a decade. Initially, it was unclear whether EMMPRIN's effects on fibroblasts required cell-cell contacts or could be mediated by soluble EMMPRIN in a paracrine manner. Subsequent studies, which showed that an active form of EMMPRIN was released into the conditioned medium of tumor cells, supported the latter possibility (Taylor et al., 2002) .
The question remained as to whether EMMPRIN was being shed intact (containing both N-and C-termini) or in a truncated form as would be generated by proteolytic cleavage. The results here clarify these issues by showing that full-length EMMPRIN leaves the cell via the budding of microvesicles, and that this process appears to be regulated in a physiologically controlled manner by a PKC-, Ca 2 þ -and MEK1/2-dependent signalling pathway. The variability in size of immunoreactive EMMPRIN has been described frequently (Nabeshima et al., 1991; Kasinrerk et al., 1992; Fadool and Linser, 1996) . Despite the likelihood that glycosylation differences underlie much of this variability, it has been speculated that a second contributing factor might be cleavage of the N-terminal extracellular domain of EMMPRIN prior to its release from the cell (Ellis et al., 1989) . That the full-length EMMPRIN polypeptide (lacking glycosylation) is predicted to be B32 kDa means that the predominant EMMPRIN species present in the medium (49 kDa) is sufficiently large to represent MEK1/2 (10 mM) 9 0 1 mM-50 mM U0126 MEK1/2 (1 mM) 9 0 50 nM-10 mM SB203580 p38MAP kinase 10 mM-30 mM 0 and MEK in PMA-induced EMMPRIN release. (a) Western blot of NCI-H460-cell-conditioned medium showing that the induction of EMMPRIN release by PMA (100 ng/ml) is inhibited by the PKC inhibitor Bisindolylmaleimide I HCl (10 nM; Bis), Ca 2 þ chelator BAPTA/AM (30 mM; BAPTA), and MEK inhibitors PD98059 (10 mM; PD) or U0126 (1 mM). An inhibitor of p38MAPK, SB230580 (30 mM; SB), had no effect. (b) Western blot showing that EMMPRIN release into conditioned medium is stimulated by thapsigargin, (1 mM). This response was inhibited by PD98059 (10 mM) full-length EMMPRIN, with some glycosylation included. Supporting the idea that full-length EMMPRIN is the predominant species released into the cell medium are data in Figure 2a . These show that there are approximately equal amounts of immunoreactive Nand C-terminal EMMPRIN in the tumor-conditioned medium. Assuming similar antigen affinity for both antibodies, this supports a model in which one Cterminus epitope is released into the medium every time an N-terminus epitope is released, that is, release of fulllength EMMPRIN. Given intrinsic differences in the two antigen-antibody interactions, however, such reasoning is at best semiquantitative. Thus, we cannot rule out the existence of a second EMMPRIN release mechanism involving N-terminal cleavage.
Although the immunohistochemical localization of EMMPRIN at tumor cell surfaces and the presence of an internal hydrophobic domain had strongly suggested that EMMPRIN was a transmembrane protein, this view was challenged recently (Taylor et al., 2002) . Specifically, these studies showed that full-length EMMPRIN in the conditioned medium of breast cancer cells was not sedimentable by centrifugation, as would be expected if it were associated with vesicles. The presence of both N-and C-termini seemed to rule out ectodomain cleavage, whereas the absence of vesicles seemed to rule out vesicular release. Since it was not evident how the C-terminal (cytoplasmic) domain of a transmembrane protein could exit the cell other than via vesicles, it was proposed that EMMPRIN might not in fact be a transmembrane protein. Importantly, the present data resolve this incongruity by showing that EMMPRIN is indeed sedimentable by ultracentrifugation of tumor-conditioned medium at early time points and is present in microvesicles (B300 nm) that are reactive with EMMPRIN antibodies. These findings validate the original concept of EMMPRIN as a transmembrane protein and for the first time reveal that the mechanism by which EMMPRIN is released from tumor cells involves vesicle shedding. Notably, however, in agreement with data reported earlier Dolo et al., 1998; Taraboletti et al., 2002) , the vesicles isolated in our study had a relatively short lifespan (Figure 3c ). Within hours, the vesicles appeared to lyse, releasing EMMPRIN into the surrounding medium. Thus, we observed an inverse ratio between the amounts of EMMPRIN in vesicles versus supernatant, that is, vesicles lost and supernatant gained EMMPRIN over time (Figure 3d ). Under the conditions of our experiments, which entailed 8-h exposure of medium to tumor cells, 1 h ultracentrifugation, and 12 h exposure of conditioned medium fractions to 16LU fibroblasts, the principal source of bioactive EMMPRIN was the supernatant and not the vesicles themselves (Figure 3e ). These results may explain the inability of Taylor et al (2002) to link EMMPRIN with intact vesicles. In Figure 6 , we propose that tumor cells release EMMPRIN-bearing vesicles, which lyse over time, giving rise to membrane fragments containing fulllength EMMPRIN. We suggest that it is EMMPRIN in this form that ligates receptors on target cells, resulting in MMP induction. This view is supported by the finding that EMMPRIN recovered from tumor-conditioned medium is hydrophobic in nature (Taylor et al., 2002) .
The growing importance of vesicle shedding and the release of proteins from the cell via this mechanism has now been described in a variety of species and physiological conditions and is thought to be crucial in development, generating signalling gradients in drosophila (Greco et al., 2001; Vincent and Magee, 2002) , vertebrate bone growth (Wang and Kirsch, 2002; Wu et al., 2002) , platelet activation (Heijnen et al., 1999) , and in the immune system (Satta et al., 1994; MacKenzie et al., 2001; Thery et al., 2002) .
The specific importance of vesicle shedding in tumor cells has also been addressed (Zitvogel et al., 1998; Dolo et al., 2000; Kim et al., 2002; Taraboletti et al., 2002; Gutwein et al., 2003) . It has been shown to occur in tumor cells in vitro and in vivo (Taylor and Black 1986; Dolo et al., 1995) and is associated with malignancy Ginestra et al., 1999) . It is likely that vesicle shedding and, more importantly, the factors released by vesicle shedding, are vital to tumor survival and growth, since it is by the release of such factors that tumors condition their microenvironment, regulate metastasis and evade immune surveillance (Wolfers et al., 2001; Andreola et al., 2002; Kim et al., 2002; Taraboletti et al., 2002) .
Interestingly, tumors release at least two types of vesicles: small exosome-like vesicles and larger microvesicles. Exosomes form within late endocytic compartments, called multivesicular bodies and are secreted upon fusion with the plasma membrane, while microvesicles are derived directly from the plasma membrane (Heijnen et al., 1999; Salzer et al., 2002; Thery et al., 2002) . Our immunogold labelling experiments revealed Figure 6 Model of EMMPRIN action. Based on data showing that pharmacological blockade of PKC, Ca 2 þ and Erk1/2 interferes with PMA-induced EMMPRIN release, we propose that these signalling molecules act upstream of a mechanism responsible for outward deformation of the cell surface to form EMMPRINcontaining microvesicles. Further, we suggest that these vesicles lyse within hours of release giving rise to bioactive EMMPRIN. Following EMMPRIN interaction with its receptor on target fibroblasts, a second set of signalling events upregulate MMP-1 transcription that EMMPRIN was exclusively associated with microvesicles.
It had been unknown whether the vesicle shedding associated with tumor cells occurred constitutively, or was subject to regulation by external stimuli. To examine this, we surveyed a variety of common stimuli for their ability to increase the rate of appearance of EMMPRIN in the tumor-conditioned medium. PMA, a well-defined analogue of DAG, increased EMMPRIN release in a time-and dose-dependent manner (Figure 4) . This was the first indication that vesicle shedding can be controlled via cytoplasmic signalling mechanisms.
PMA is known to specifically stimulate signalling pathways involving PKC, Ca 2 þ and Erk 1/2 (Jaken, 1996; Gutwein et al., 2000; Cullen and Lockyer, 2002) . It was therefore not surprising to find that inhibitors of the above three signalling molecules inhibited EMMPRIN release by PMA ( Figure 5 , Table 1 ). Notably, however, chemical inhibitors are capable of producing nonspecific effects; therefore these results must be considered somewhat tentative until validated by genetic approaches (e.g. RNAi). The identification of events intervening between Erk 1/2 activation and vesicle release is an important area for future study.
In summary, based on both biochemical and morphological data, we conclude that microvesicle shedding is a major route by which tumor cells release bioactive EMMPRIN into their environment. Pharmacological data suggest that this process is regulated by cytoplasmic signalling mechanisms that could be induced or inhibited by naturally occurring agents in the tumor cell microenvironment. With more extensive analysis of such signalling mechanisms, it may be possible to design drugs that would impair the survival and growth of tumors by inhibiting the release of EMMPRIN and other membrane proteins via vesicle shedding.
Materials and methods
Antibodies and immunoreagents
Mouse monoclonal EMMPRIN-specific antibody was obtained from Biodesign International (Saco, ME, USA). N-and C-terminal-specific EMMPRIN rabbit polyclonal antibodies (N19 and C19) were obtained from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). FLAG M2 antibody was obtained from Sigma (St Louis, MO, USA). Mouse monoclonal isotype control IgG and goat polyclonal IgG antibodies were obtained from Zymed International (So. San Francisco, CA, USA) and secondary cy3 conjugated antibodies for immunofluorescence studies were from Jackson Immuno Research (West Grove, PA, USA). Protein assay reagent from Biorad (Hercules, CA, USA) was used for protein quantification, and immunodepletion studies were carried out using protein G agarose beads (Invitrogen, Carlsbad, CA, USA). For immunoblot analyses, anti-mouse or anti-rabbit horse radish peroxidase (HRP)-conjugated secondary antibodies were obtained from Santa Cruz Biotechnology Inc. Electron microscopy immunogold labelling experiments were carried out with a secondary goat anti-mouse IgG Ab conjugated to 10 nm gold particles (Amersham, Piscataway, NJ, USA). Chemical inhibitors used in this study were obtained from Calbiochem, Bisindolylmaleimide I HCl, BAPTA/AM, Thapsigargin, PD98059, U0126, PP2 and SB203580. PMA was obtained from Sigma.
Cell culture
NCI-H460 and NCI-H292 cells were originally obtained from American Type Culture Collection. Cells were grown to confluence in 75 cm 2 flasks (Falcon) in RPMI medium with 10% fetal bovine serum (FBS) at 371C under 5%CO 2 /95% atmosphere. For experiments with chemical inhibitors, cells were cultured under serum-free conditions for 4 h before pretreatments with inhibitor for an additional 45 min. Pretreatment medium was removed and cells were stimulated in the presence or absence of inhibitors as indicated. Conditioned medium was collected 2 h post-treatment unless otherwise indicated. Conditioned medium was centrifuged to remove cell debris and supernatant protein was precipitated by centrifugation at 10 000 g for 15 min at 41C with 80% ice-cold acetone, or alternatively, medium was concentrated in 10 000 molecular weight cutoff Amicon ultrafree spin columns (Millipore, Bedford, MA, USA). Protein precipitates and medium concentrates were resuspended in Tris-Glycine-SDS solubilization buffer (ICN Biomedicals Inc., Aurora, OH, USA), and 10% of total samples were typically used for Western blot analysis. Cell lysates were prepared by washing the cells in phosphate-buffered saline (PBS), before lysing in RIPA buffer containing a cocktail of complete proteinase inhibitors (Roche, Mannheim, Germany). Typically, 10 mg of total protein lysate were used for Western analyses. All experiments were carried out in triplicate.
Western blots
Samples were electrophoresed under nonreducing conditions in 12% Tris-HCl Ready Gels (Biorad) and transferred to Hybond nitrocellulose paper (Amersham). Nonspecific binding sites were blocked by washing blots in 5% nonfat milk (Nestle) in PBS containing 0.1% Tween 20 (PBST; Sigma) for 1 h with shaking. Blots were incubated with primary antibody overnight at 41C, washed in PBST and incubated with HRPconjugated secondary antibody for 1 h at room temperature. Blots were washed again before visualization of immunocomplexes using ECL Western blotting kit (Amersham) and exposing to Hyperfilm (Amersham). Protein assays were carried out on cell lysates to ensure equal loading of samples.
For construction of the epitope-tagged EMMPRIN, fulllength coding region of EMMPRIN was cloned into plasmid vector pCMV-Tag4A (Stratagene, La Jolla, CA, USA). After transfection, stable lines of NCI-H460 cells expressing recombinant human C-terminal FLAG-tagged EMMPRIN were selected with geneticin (Roche).
Luciferase reporter assays
16LU human lung fibroblasts (ATCC) were maintained in H16/F12 (50/50) supplemented with 10% FBS and penicillin/ streptomycin in 75 cm 2 flasks. Cells approaching confluence (B80%) were transfected with luciferase reporter plasmid constructs containing 2.9 kb of human MMP1 promoter sequence (Rutter et al., 1997; Lim et al., 1998) . Transfections were carried out using 5 mg of DNA with 60 ml Qiagen Effectene Reagent in low serum medium for approximately 12 h. Cells were recovered in full serum medium for 24 h and then plated into 12-well plates. The next day, cells were serum starved for 4 h before conditioned medium was added to plates. Typically, cells were exposed to conditioned medium for 12 h. Cells were washed in ice-cold PBS, then lysed in Promega lysis buffer. Lysates were frozen at À801C, then thawed before being analysed using Promega luciferase assay system reagents (Madison, WI, USA). All treatments and experiments were carried out in triplicate.
Preparation of conditioned and immunodepleted medium for reporter assays
Confluent flasks of NCI-H460 and NCI-H292 cells were washed and grown in serum-free conditions. After an 8 h incubation, conditioned medium was removed and centrifuged at 1500 g for 10 min, transferred to a new tube and centrifuged again at 1500 g for 15 min to remove cells and any large debris. Antibody-protein G agarose beads were prepared by incubating 500 ml protein G agarose beads with 50 mg of antibody, either an anti-EMMPRIN antibody or an isotype-matched control antibody. Antibody-bead complexes were washed with 4 Â 1 ml PBS to remove any unbound antibody.
Antibody-bead complexes were incubated with 10 ml of conditioned medium for 8 h at 41C on a rocker. Beadimmunocomplexes were centrifuged 3 Â 1500 g for 10 min. The medium was then transferred to new tubes between each spin to ensure complete removal of beads.
Immunocytochemistry
Cells were grown in chamber slides (Labtek II, Nalgene) to near confluence and then fixed in 2% paraformaldehyde (PFA) in PBS. After washing with PBS, slides were blocked with 5% normal goat serum (NGS) in PBST, then incubated with primary antibodies in PBST and 5% NGS overnight at 41C, followed by a 1 h incubation with the appropriate Cy2-conjugated secondary antibody. Control samples were incubated with isotype-matched control antibody or secondary antibody only. Coverslips were mounted in Gel Mount mounting medium (Biomeda, So San Francisco, CA, USA) and examined using a UV fluorescent microscope (Nikon E600, TISF, Burlingame, CA, USA). Images were taken using an Axiocam digital camera (Carl Zeiss, Germany).
Vesicle preparation
Vesicles were prepared essentially as described (Dolo et al., 1994) . Typically, conditioned medium was collected from tumor cell cultures after 8 h. The medium was centrifuged at 1500 g for 10 min, transferred to a new tube and centrifuged again at 1500 g for 15 min to remove cells and any large debris. Supernatant was then ultracentrifuged at 1 50 000 g for 1 h at 41C. Pelleted vesicles were resuspended in PBS (pH7.5) and protein concentration was determined. Samples were frozen at À201C or used immediately for electron microscopy studies.
Electron microscopy
Aliquots of vesicles were applied on 400 mesh nickel parlodion-coated grids and allowed to settle. Samples were blocked in 5% NGS for 30 min, rinsed in PBS and incubated with anti-EMMPRIN Ab at 41C overnight. Grids were washed with PBS, incubated with gold-labelled anti-mouse IgG secondary Ab for 1 h and then rinsed with PBS again. Grids were fixed in 2% glutaraldehyde in PBS, rinsed, then negatively stained with 1% phosphotungstic acid (pH 6), before being analysed under an electron microscope. Specificity of immunolabelling was determined by comparing results obtained with matched isotype control primary antibodies or gold-labeled secondary Ab only.
